Merck Says FDA Accepted For Priority Review A New Supplemental Biologics License Application Seeking Approval For Keytruda In Combination With Chemotherapy
Portfolio Pulse from Benzinga Newsdesk
Merck announced that the FDA has accepted a priority review for a new supplemental biologics license application for Keytruda in combination with chemotherapy for the first-line treatment of advanced or metastatic malignant pleural mesothelioma. The FDA's target action date is September 25, 2024.
May 29, 2024 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's Keytruda has been accepted for FDA priority review for use in combination with chemotherapy for treating advanced malignant pleural mesothelioma. The FDA's decision is expected by September 25, 2024.
The FDA's acceptance of a priority review for Keytruda in combination with chemotherapy indicates a potentially significant advancement in treatment options for malignant pleural mesothelioma. This could lead to increased sales and market share for Merck if approved.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100